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aeart failure (HF) remains a dynamic field. Treatment
ontinues to be refined and improved and, at last, there is
vidence that the increased survival demonstrated in ran-
omized clinical trial cohorts has been translated to the
nselected general population. Beyond angiotensin-
onverting enzyme (ACE) inhibitors and beta-blockers, two
ore classes of drug, the angiotensin receptor blockers and
ldosterone antagonists, were unequivocally demonstrated
o have a survival benefit during 2003. This year also
stablishes a new era in device therapies, which also improve
utcomes in patients with HF.
MPROVING CLINICAL OUTCOMES IN HF
n a population-based study, Blackledge et al. (1) reported
mproving 30-day and 1-year survival after a first admission
o hospital with HF in the English county of Leicestershire
ver the period 1993 to 2001. Postdischarge cardiovascular
ortality fell by over 50%. Also of note, hospital admission
ates increased from 1993 to 1998 but plateaued thereafter.
hese encouraging findings with respect to survival, first
dmissions, and readmissions mirror prior observations
rom Scotland, the Netherlands, the U.S. (Framingham,
assachusetts, and Northeast Ohio), and, more recently,
weden and Canada (Ontario) (2–7). These consistent
rends (Figs. 1 and 2) have been interpreted to reflect the
opulation impact of the incremental survival and other
enefits of ACE inhibitors, spironolactone, and beta-
lockers. Indeed, the improvements in outcomes noted in
hese observational studies temporally correlate with the
idespread uptake of ACE inhibitors and, to a lesser extent,
pironolactone; it is only in the most recent studies that
eta-blockers could have begun to have had an effect. It will
e of interest to see if these findings can be replicated in
dditional countries and whether the trends identified
ontinue as the full effect of beta-blockade becomes appar-
nt.
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ENTRICULAR SYSTOLIC FUNCTION
n encouraging development that accelerated in 2003 was
he shift to a broader focus of HF incorporating the
ubstantial proportion of patients with signs and symptoms
ccurring in the absence of any major reduction in left
entricular systolic function (8–13). The pathophysiology
nd even terminology related to this latter, heterogeneous
ype of HF, however, remains controversial. Most of the
ecently reported epidemiologic and hospital cohort studies
ade no attempt to assess diastolic function, instead de-
cribing these patients as having HF with preserved systolic
unction (PSF). Zile (14) has argued that detailed evaluation
ould confirm diastolic dysfunction in most of these pa-
ients, though, to date, this has only been verified in small
umbers of highly selected individuals. Some paradoxes also
emain; HF-PSF is much more frequent in women than
en, yet two population-based epidemiologic studies pub-
ished in 2003 found that indexes of diastolic dysfunction
ere more common in men than women. Indeed, diastolic
ysfunction was also remarkably common in older individ-
als generally, even in the absence of clinical HF (12,13).
edfield et al. (12) found that, of those age 75 years or older,
3% had mild, 15% moderate, and 3.4% severe diastolic
ysfunction. Is the finding of diastolic dysfunction in a
reathless elderly patient, therefore, a very specific finding?
thers have drawn attention to vascular rather than myo-
ardial differences between these two types of HF (15). The
onspecific nature of the signs and symptoms of HF and the
omplexity of performing and interpreting measures of
iastolic function emphasize the great need for a simple and
greed upon diagnostic test for HF-PSF. Without a quan-
itative, reproducible, and clinically applicable measure of
iastolic function, left ventricular ejection fraction will
ontinue to serve as the distinguishing feature. B-type
atriuretic peptides (BNP) provide additional underpinning
or the clinical diagnosis of HF. The Breathing Not
roperly study was one of the first to address this important
uestion (16). Using a “gold standard” of a clinical diagnosis
ade by two independent cardiologists unaware of BNP
evels, Maisel et al. (15) tested how BNP performed.
nfortunately, there was a significant overlap in BNP
oncentrations between patients with non-cardiac breath-
essness and those with HF-PSF, especially women.
learly, more studies of this type are needed, perhaps using
different “gold standard” or natriuretic peptide (e.g.,
-terminal pro-BNP).
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December 21, 2004:2398–405 Year in Heart FailureWhatever the underlying pathophysiology and optimal
iagnostic approach, evidence continues to accumulate
hat HF-PSF is a common and important syndrome.
mith et al. (10) have added to the growing array of
tudies showing that, while HF-PSF is associated with a
ower mortality than HF with reduced systolic function,
t still leads to a comparable degree of functional limita-
ion and morbidity as measured by admission to hospital.
ortunately, there has also been a drive to conduct major
rospective randomized outcome studies to evaluate new
reatments in this type of HF. The first of these to report
as Candesartan in Heart Failure: Assessment of Reduc-
ion in Mortality and morbidity (CHARM)-Preserved,
ne of the three component trials of the CHARM
rogram (see the following text) (17). In this study,
andesartan was compared with placebo in 3,023 patients
ith HF and a left ventricular ejection fraction higher
han 0.40. During a median of 37 months, candesartan
reatment did not lead to a statistically significant reduc-
igure 1. Evidence of improving survival from heart failure in the general p
n patients having a first admission for heart failure, according to year of ad
atio for first year of study (1993/1994) set at 1. (b) Odds ratios and 95%
dmission), according to year of admission (adjusted for age, gender, comor
et at 1. (c) Standardized 30-day and 1-year case fatality rates (%) for wom
en). (d) Age-adjusted survival after the onset of heart failure in men. Va
stimates are shown for men who were 65 to 74 years of age. Similar treion in the primary end point of cardiovascular death or Vospital admission for HF (22% vs. 24%, hazard ratio
.89, p  0.118). Compared with placebo, however,
andesartan did reduce the proportion of patients requir-
ng admission to hospital for HF by 18% (p  0.017) and
he total number of admissions for HF by 29% (p 
.014). This trial did demonstrate that the annual mor-
ality rate of 5.4 %, although less than the patients with
educed left ventricular ejection fraction (11.2%), was
igher than the general population, and that recurrent
ospitalization for cardiovascular reasons was common.
ANDOMIZED TRIALS OF THERAPEUTIC
NTERVENTIONS IN CHRONIC
F WITH REDUCED SYSTOLIC FUNCTION
harmacologic. ANGIOTENSIN RECEPTOR BLOCKERS. The
HARM program confirmed and extended the findings of
he Evaluation of Losartan in the Elderly (ELITE)-2 and
tion. (a) Hazard ratio and 95% confidence intervals for all-cause mortality
on (adjusted for age, gender, comorbidity, and social deprivation). Hazard
dence intervals for all-cause mortality (30 days after a first heart failure
, and social deprivation). Odds ratio for first year of period of study (1986)
ith a first admission to hospital for heart failure (similar trends noted in
ere adjusted for age (55, 55 to 64, 65 to 74, 75 to 84, and 85 years).
ere observed in women. Figure adapted from references 1, 2, 4, and 5.opula
missi
confi
bidity
en walsartan Heart Failure Trial (Val-HeFT) in patients with
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Year in Heart Failure December 21, 2004:2398–405F and reduced systolic function (18–20). In 2,028 patients
reviously intolerant of an ACE inhibitor, compared with
lacebo during 34 months of follow-up, candesartan re-
uced the primary end point of cardiovascular death or
ospital admission for HF from 40% to 33% (hazard ratio
.77, p  0.0004) in CHARM-Alternative (18). In
HARM-Added, 2,548 patients all treated with an ACE
nhibitor (and, in 55% of cases a beta-blocker as well),
andesartan reduced the incidence of the same end point
rom 42% to 36% (hazard ratio 0.85, p  0.011) during 41
onths of follow-up (19). This finding is consistent with
ecent evidence of incremental and favorable remodeling
ffects with “triple therapy” (21). In both these low ejection
raction trials, candesartan reduced all-cause mortality from
1% to 28% (hazard ratio 0.88, p  0.018). The benefits of
andesartan were consistent across a wide range of sub-
roups and irrespective of background therapy, including
CE inhibitor, beta-blocker, and spironolactone, whether
sed individually or in any combination (20). Candesartan
as also effective when added to either high- or lower-dose
igure 2. Recent trends in hospital admissions for heart failure demonstra
n men and women. (b) Gender-specific trends in hospitalizations (princi
umber of individuals; circles  first-ever hospitalization. Similar trends w
ailure hospitalization rates (principal diagnosis) in individuals 40 years.
principal diagnosis).CE inhibitor treatment. dETA-BLOCKERS. The greatest advance in the treatment of
F since the introduction of ACE inhibitors was the demon-
tration in three landmark prospective, randomized, placebo-
ontrolled trials of an approximately 33% relative reduction in
ll-cause mortality (and similarly impressive reductions in
ospital admissions) with the addition of a beta-blocker. Of
ote, these benefits were identified early, and all three trials
ere terminated prematurely, after about one year’s follow-up.
he effective agents used were bisoprolol (in Cardiac Insuffi-
iency Bisoprolol Study [CIBIS]-2), carvedilol (in the Effect
f Carvedilol on Survival in Severe Chronic Heart Failure
COPERNICUS] trial), and a slow-release formulation of
etoprolol (succinate) in Metoprolol CR/XL Randomised
ntervention Trial in Congestive Heart Failure (MERIT-HF);
ach had an almost identical size of treatment effect (22–24).
f note, in the Beta Blocker Evaluation of Survival Trial
BEST), another beta-blocker, bucindolol, was not clearly
hown to have these benefits (25). The results of Carvedilol Or
etoprolol European Trial (COMET), a rare type of ran-
omized trial comparing two active treatments within the same
ecent plateau or decline. (a) Age-adjusted discharge rate for heart failure
agnosis) for heart failure in men. Squares  total episodes; triangles 
bserved in women. (c) Gender- and age-specific trends in first-ever heart
ge-adjusted annual incidence of first-ever hospitalization for heart failureting r
pal di
ere orug class, were reported in 2003; COMET compared carve-
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December 21, 2004:2398–405 Year in Heart Failureilol to a short-acting formulation of metoprolol (tartrate),
ifferent from that used in MERIT-HF (which used meto-
rolol succinate) (26). This large (n 3,029), long-term (mean
ollow-up 58 months) trial demonstrated that carvedilol led to
17% relative risk reduction in all-cause mortality from 40% to
4% (p  0.0017) compared with short-acting metoprolol
artrate. The interpretation of this remarkable difference be-
ween two beta-blockers has been controversial. Some have
nterpreted the COMET as demonstrating the advantages of
he different molecular actions of carvedilol, namely nonselec-
ive (beta-1 and -2) adrenoceptor blockade, alpha-
drenoceptor blockade, and perhaps other effects, over meto-
rolol (which is a relatively beta-1 adrenoceptor antagonist).
thers have criticized the COMET on the basis of comparing
ifferent intensities of beta-1 adrenoceptor antagonism, as a
onsequence of the unproven formulation of metoprolol used
the only sizable prior study with metoprolol tartrate, the
etoprolol in Dilated Cardiomyopathy [MDC] trial, used
wo or three times daily dosing and achieved a mean dose of
etoprolol tartrate of 108 mg compared with 85 mg in the
OMET). Other evidence suggests that 50-mg metoprolol
artrate prescribed twice daily does not give equivalent beta-
lockade to metoprolol succinate 200 mg taken once daily, as
he reduction in heart rate in the metoprolol group in the
OMET was slightly less than in the MERIT-HF. One
efinite conclusion from the COMET, however, is that
hort-acting metoprolol tartrate, used only twice daily, is an
nferior treatment to carvedilol in chronic heart failure (CHF).
evices. CARDIAC RESYNCHRONIZATION THERAPY (CRT).
nother intervention that may revolutionize the treatment
f CHF is atriobiventricular pacing (27–30). It is estimated
hat about a quarter of patients with CHF have increased
RS duration (120 ms). This is a marker of dyssynchrony
f right and left ventricular activation, which causes ineffi-
ient pump function. Atriobiventricular pacing recoordi-
ates ventricular contraction. In 2003, follow-up reports
rom the first controlled trials of this new therapy confirmed
mprovements in symptoms, quality of life, and functional
apacity, and showed additional mechanistic benefits such
s reduced left ventricular remodeling, reduced mitral re-
urgitation, and increased heart rate variability (27–29). An
nteresting meta-analysis suggested that CRT also reduces
ospital admissions for HF and death from progressive
ump failure but perhaps not all-cause mortality (30). The
ecently reported Comparison of Medical Therapy, Pacing,
nd Defibrillation in Heart Failure (COMPANION) trial
upports this conclusion and also shows that CRT reduces
he clinically important composite outcome of death or
ospital admission for any reason by 19% (p  0.014)
lthough the benefits were not as great as in patients having
oth CRT and an implantable cardioverter-defibrillator
ICD) (31). The results of the second major outcome study
f CRT in CHF, Cardiac Resynchronization in Heart
ailure (CARE-HF) study, are due in 2005 and eagerly
waited (32). A number of other issues remain to be
esolved with CRT. There is concern that a broadened QRS bay not offer the best means of identifying patients with
entricular dyssynchrony. Consensus has yet to be reached
n whether CRT therapy alone or a combined CRT-ICD
evice should be implanted (or in whom these different
herapeutic modalities are indicated). The recent COM-
ANION trial and Sudden Cardiac Death in Heart Failure
rial (SCD-HeFT) argue powerfully for wider use of ICD
herapy in CHF (31).
NEFFECTIVE TREATMENTS IN CHF. The history of clinical
rials in CHF is littered with failures as well as successes.
wo examples of the former were published in 2003. The
dverse Mortality Effect of Central Sympathetic Inhibition
ith Sustained-Release Moxonidine in Patients with Heart
ailure (MOXCON) trial showed that not all anti-
drenergic therapies are beneficial in CHF (as also shown
y V-HeFT 1 with the alpha-adrenoceptor prazosin) and
nce again raised the vexed issue of dose selection (33). The
nti-TNF Therapy Against Congestive Heart Failure
ATTACH) trial showed that one type of anticytokine
herapy does not improve outcome in CHF, and the recent
ublication of the results of Randomized Etanercept
orldwide Evaluation (RENEWAL) trial revealed a sim-
lar finding with a different inhibitor (34,35). These studies
erve to emphasize two points. First, our understanding of
ophisticated, inter-related, biologic systems is limited, and
t cannot be assumed that activation of such a system in
HF is necessarily disadvantageous. Second, it is also clear
hat effects of inhibitors of these systems, especially when
omplex molecular therapies are used, are not easy to
redict. The recent experience with endothelin receptor
ntagonists and dual neutral endopeptidase-ACE inhibitors
erves to reinforce all of these issues about dose and biologic
omplexity.
F AFTER ACUTE MYOCARDIAL INFARCTION
linical evidence of acute HF, even if transient, early after
cute myocardial infarction identifies a patient at high risk
f short- and longer-term adverse cardiovascular outcomes.
he same is true for left ventricular systolic dysfunction
ithout acute HF and, especially, if both of these problems
re present. The recent findings of international registries
ave clearly illustrated this risk in contemporary cohorts of
atients with acute coronary syndromes where pulmonary
ongestion was associated with up to a four-fold excess of
eath (36,37). The key role of early, sustained ACE
nhibition in improving prognosis in these patients remains
ndisputed (38). The importance of concomitant beta-
lockade was recently reinforced by the Carvedilol Post-
nfarct Survival Controlled Evaluation (CAPRICORN)
39). Recently, two further therapeutic questions were
nswered. One was whether an angiotensin receptor blocker
ould be as, or more, effective than a proven dose of a
roven ACE inhibitor and whether combination ACE
nhibitor-angiotensin receptor blocker treatment would be
etter than ACE inhibitor monotherapy, as in CHF (see
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Year in Heart Failure December 21, 2004:2398–405he preceding text) (40). The second question was whether
he addition an aldosterone blocker to an ACE inhibitor
nd beta-blocker would further improve outcome in these
atients (41).
The Valsartan in Acute Myocardial Infarction Trial
VALIANT) showed that the angiotensin receptor blocker
alsartan used in a dose of up to 160 mg twice a day (as in
al-HeFT) was as effective in reducing risk of death and
ther major cardiovascular outcomes as the proven dose of
aptopril (50 mg three times a day) used in the Survival and
entricular Enlargement (SAVE) study (and, subsequently,
n ELITE-2 and Optimal Therapy in Myocardial Infarction
ith the Angiotensin II Antagonist Losartan [OPTI-
AAL]) (40). Valsartan 80 mg twice a day, added to this
ose of captopril, did not, however, lead to any further
eduction in risk of the primary or secondary end points in
he VALIANT (though the combination did lead to more
ntolerance). The possible explanations for this difference
etween the effects of combination ACE inhibitor-
ngiotensin receptor blocker therapy in CHF and acute
yocardial infarction are discussed elsewhere (41,42).
In the Eplerenone Post-AMI Heart Failure Efficacy and
urvival Study (EPHESUS), of patients with acute myo-
ardial infarction with both acute HF and reduced left
entricular ejection fraction, the addition of the aldosterone
locker eplerenone led to a 15% relative risk reduction in
ll-cause mortality and a reduction in hospital admission for
F. These benefits were achieved despite high baseline use
f ACE inhibitors and beta-blockers, demonstrating the
ncremental advance for these patients at especially high risk
fter acute myocardial infarction (39). The prior observa-
ion, in the Randomized Aldactone Evaluation Study
RALES), that spironolactone, added to an ACE inhibitor,
mproves survival in severe HF reinforces the findings of
PHESUS (43).
CUTE DECOMPENSATED HF
here has been a recent explosion of interest in what has
ecome known as “acute decompensated HF,” a term
robably describing a mixture of syndromes including acute
e novo HF and acute on-chronic HF (44). The clinical
ommunity is still struggling with how best to evaluate
reatments in this type of HF (45,46). Since many are
esigned to be given intravenously for only a short period, it
s difficult to know whether long-term outcomes can be
mproved. Several drugs including the endothelin receptor
ntagonist tezosentan (47) and the arginine vasopressin
ntagonist tolvaptan (48) have been shown to have favorable
emodynamic, neurohumoral renal, and other actions in
cute HF. However, to date, none of these therapies has
een shown to improve short-term survival or other clinical
utcomes in patients presenting with acute HF. Large-scale
utcome trials with these agents are now underway, adding
o completed studies with “inodilators” and nesiritide
49,50). HHE IMPORTANCE OF COMORBIDITY IN HF
eart failure is most commonly caused by coronary heart
isease, hypertension, or both. Consequently, many patients
ave other complications of atherosclerosis and hyperten-
ion. Often these elderly individuals have related comorbid-
ty, such as diabetes (51,52) and other conditions sharing a
ommon etiology (e.g., smoking-related chronic pulmonary
isease). Some comorbidities are complications of HF or
he combination of HF, its underlying etiology, and ad-
anced age (e.g., renal impairment) (53,54), stroke, atrial
55,56) and ventricular arrhythmias. The causes of others
ave yet to be fully elucidated (e.g., anemia, obstructive
leep apnea, and cachexia) (57). The importance of certain
omorbidities as independent predictors of poor outcome
as been highlighted in 2003. This recognition has also led
o the view that these might themselves be therapeutic
argets. The clearest example of this is anemia (58–61).
our recent studies found that low hemoglobin or hemat-
crit is a powerful prognostic factor in HF (58–61). In a
mall, single-blind, randomized, controlled trial, Mancini et
l. (62) showed that correcting anemia with erythropoietin
esulted in clinical improvement and an increase in exercise
apacity. At least one prospective outcome trial using
rythropoietic therapy is now planned. Another notable
evelopment, related to comorbidity, was recognition of the
roblems thiazolidinediones can cause, related to fluid
etention, when given to treat diabetes in patients with HF
63).
Two studies published in 2003 add to prior evidence
hat continuous positive airway pressure improves ven-
ricular function and well-being and reduces neurohu-
oral activity in patients with obstructive sleep apnea
64,65). At least one large trial is now testing the effect of
ontinuous positive airway pressure on mortality and
orbidity in HF.
RGANIZING AND
MPROVING THE DELIVERY OF CARE
ased on the results of randomized controlled trials, the
reatment of patients with HF continues to improve and has
een summarized in a number of authoritative, evidence-
ased guidelines. The challenge of developing these treat-
ents, however, is matched by the challenge of ensuring
hese are widely adopted into clinical practice (66). In 2003,
t was again shown that organized, nurse-led, multidisci-
linary care aids this goal (67), though whether all patients
ain from this intervention remains uncertain (68). New
echnology, such as home-telemonitoring, may also have a
ole to play in improving chronic disease management
69,70).
Determined efforts to implement guidelines can improve
reatment locally and nationally, as illustrated in the Italianealth Service (71,72).
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ighlighting some of the important aspects of the recent
rogress in the diagnosis and management of patients with
F serves to underscore both the globalization of the
roblem in our aging populations and the collaborative
ffort needed in order to develop new treatments for it. The
enefits observed in randomized controlled trials, at last,
eem to have been realized in nontrial populations. The
ersistently high mortality and morbidity in HF, however,
rovide a continuing impetus to find additional pharmaco-
ogic and device treatments that will improve the quality and
uration of life beyond what is currently available. The bar
s set high though, with expectations raised by the success of
ptimal conventional therapy, success that may be increas-
ngly difficult to exceed. However, the rate of generation of
ew knowledge is dramatic, greatly expanding the range of
otential therapeutic approaches, and offering a realistic
romise of continued meaningful progress in this important
eld.
eprint requests and correspondence: Dr. Marc A. Pfeffer,
righam and Women’s Hospital, Medicine, 75 Francis Street,
oston, Massachusetts 02115. E-mail: mpfeffer@rics.bwh.
arvard.edu.
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